Sath Shukla - 29 Aug 2022 Form 4 Insider Report for Spero Therapeutics, Inc. (SPRO)

Role
Chief Financial Officer
Signature
/s/ Tamara Joseph, Attorney-in-Fact for Sath Shukla
Issuer symbol
SPRO
Transactions as of
29 Aug 2022
Net transactions value
-$5,378
Form type
4
Filing time
30 Aug 2022, 17:00:13 UTC
Previous filing
03 Feb 2022
Next filing
03 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRO Common Stock Sale $5,378 -6,017 -9.7% $0.8938 56,064 29 Aug 2022 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction is a sale of common stock pursuant to a preexisting 10b5-1 plan upon the vesting on August 26, 2022 of a portion of restricted stock units ("RSUs") granted to the Reporting Person on August 26, 2021.
F2 Represents the weighted average sales price per share. The shares sold at prices ranging from $0.8839 to $0.9002 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F3 Consists of RSUs. Each RSU represents the right to receive one share of common stock upon vesting. 18,050 of the RSUs vest in three equal annual installments beginning on August 26, 2023 and 38,014 of the RSUs vest in four equal annual installments beginning on February 1, 2023, in each case subject to the Reporting Person's continued service through the applicable vesting date.